CFO
UTHR icon

CVA Family Office’s United Therapeutics UTHR Stock Holding History

CVA Family Office’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3K Hold
67
– – ﹤0.01% 672
2026
Q1 		$39.7K Buy
+67
New +$33.4K ﹤0.01% 652
2025
Q3 		– Sell
-2
Closed -$575 – 1348
2025
Q2 		$575 Hold
2
– – ﹤0.01% 1194
2025
Q1 		$617 Buy
+2
New +$685 ﹤0.01% 1186

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

CVA Family Office's UTHR Position: Q2 2026 in Review

CVA Family Office held its United Therapeutics (UTHR) position steady in Q2 2026 at 67 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #672.

CVA Family Office first reported a position in UTHR in Q1 2025 and has held it in 4 quarters since. The position peaked at $39.7K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • CVA Family Office held 67 shares of United Therapeutics worth $36.3K as of Q2 2026.
  • CVA Family Office left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #672 holding.
  • CVA Family Office first reported a position in United Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • CVA Family Office's United Therapeutics position peaked at $39.7K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.